Frontiers in Oncology | Hematologic Malignancies

Original Research

Published on 10 Feb 2022

Epidemiologic Characteristics, Prognostic Factors, and Treatment Outcomes in Primary Central Nervous System Lymphoma: A SEER-Based Study

in Hematologic Malignancies

Dongsheng Tang
Yue Chen
Yuye Shi
Hong Tao
Shandong Tao
Quan’e Zhang
Banghe Ding
Zhengmei He
Liang Yu
Chunling Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.817043

6,776 views
31 citations

Systematic Review

Published on 10 Feb 2022

Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis

in Hematologic Malignancies

Kangkang Chen
Yingying Ruan
Kewei Tian
Peisheng Xiong
Nan Xia
Jin Li
Wen Huang
Feiyan Cao
Qifeng Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.841546

5,046 views
9 citations

Opinion

Published on 10 Feb 2022

T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?

in Hematologic Malignancies

Johanna Schreiber
Alexander Pichler
Christoph Kornauth
Hannes Kaufmann
Philipp B. Staber
Georg Hopfinger

Frontiers in Oncology

doi 10.3389/fonc.2022.805449

14,040 views
4 citations

Original Research

Published on 09 Feb 2022

PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS

in Hematologic Malignancies

Jihao Zhou
Min Zuo
Lifeng Li
Fang Li
Peng Ke
Yangying Zhou
Yaping Xu
Xuan Gao
Yanfang Guan
Xuefeng Xia

Frontiers in Oncology

doi 10.3389/fonc.2022.824632

5,924 views
15 citations

Review

Published on 08 Feb 2022

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma

in Hematologic Malignancies

Yuan Wang
Jing He
Manyu Xu
Qingfeng Xue
Cindy Zhu
Juan Liu
Yaping Zhang
Wenyu Shi

Frontiers in Oncology

doi 10.3389/fonc.2022.815654

6,628 views
12 citations

Mini Review

Published on 08 Feb 2022

Impact of Low-Burden TP53 Mutations in the Management of CLL

in Hematologic Malignancies

Gregory Lazarian
Florence Cymbalista
Fanny Baran-Marszak

Frontiers in Oncology

doi 10.3389/fonc.2022.841630

6,661 views
7 citations

Review

Published on 08 Feb 2022

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment

in Hematologic Malignancies

Claudio Cerchione
Saad Z. Usmani
A. Keith Stewart
Martin Kaiser
Leo Rasche
Martin Kortüm
María-Victoria Mateos
Andrew Spencer
Pieter Sonneveld
Kenneth C. Anderson

Frontiers in Oncology

doi 10.3389/fonc.2022.820768

11,247 views
18 citations

Review

Published on 08 Feb 2022

The Roles of IRF-8 in Regulating IL-9-Mediated Immunologic Mechanisms in the Development of DLBCL: A State-of-the-Art Literature Review

in Hematologic Malignancies

Mingyue Cai
Na Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.817069

5,251 views
9 citations

Review

Published on 08 Feb 2022

What Clonal Hematopoiesis Can Teach Us About MDS

in Hematologic Malignancies

Irenaeus C. C. Chan
Brian J. Wiley
Kelly L. Bolton

Frontiers in Oncology

doi 10.3389/fonc.2022.794021

7,583 views
1 citation

Original Research

Published on 08 Feb 2022

Mutant NPM1-Regulated FTO-Mediated m6A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis

in Hematologic Malignancies

Qiaoling Xiao
Li Lei
Jun Ren
Meixi Peng
Yipei Jing
Xueke Jiang
Junpeng Huang
Yonghong Tao
Can Lin
Jing Yang

Frontiers in Oncology

doi 10.3389/fonc.2022.817584

6,508 views
27 citations

Case Report

Published on 07 Feb 2022

Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report

in Hematologic Malignancies

Baoquan Song
Xin Wang
Xin Kong
Man Wang
Li Yao
Hongjie Shen
Jian Zhang
Huiying Qiu

Frontiers in Oncology

doi 10.3389/fonc.2022.828852

4,165 views
22 citations

Original Research

Published on 07 Feb 2022

Prognostic Value of Radiomic Features of 18F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells

in Hematologic Malignancies

Yeye Zhou
Jihui Li
Xiaoyi Zhang
Tongtong Jia
Bin Zhang
Na Dai
Shibiao Sang
Shengming Deng

Frontiers in Oncology

doi 10.3389/fonc.2022.834288

5,701 views
30 citations

Original Research

Published on 04 Feb 2022

A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children

in Hematologic Malignancies

Leyuan Wang
Lin Yuan
Xizi Du
Kai Zhou
Yu Yang
Qingwu Qin
Liangchun Yang
Yang Xiang
Xiangping Qu
Huijun Liu

Frontiers in Oncology

doi 10.3389/fonc.2022.800786

3,067 views
7 citations

Perspective

Published on 04 Feb 2022

Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists

in Hematologic Malignancies

Catarina Geraldes
Manuel Neves
Sérgio Chacim
Fernando Leal da Costa

Frontiers in Oncology

doi 10.3389/fonc.2021.817762

15,174 views
10 citations

Editorial

Published on 03 Feb 2022

Editorial: New Insights into the Complexity of Tumor Immunology in B-cell Malignancies: Tumor Immunology and Immunotherapy

in Hematologic Malignancies

Martina Seiffert
Etienne Moussay
Jérôme Paggetti

Frontiers in Oncology

doi 10.3389/fonc.2022.853620

2,170 views

Original Research

Published on 02 Feb 2022

Diffuse Large B-Cell Lymphoma: Clinical Presentation and Treatment Outcomes From the OncoCollect Lymphoma Registry

in Hematologic Malignancies

Reena Nair
Dinesh Bhurani
Senthil Rajappa
Asha Kapadia
Rakesh Reddy Boya
Subramanian Sundaram
Hari Menon
Ganapathi S. Raman
Arun Seshachalam
Ramesh Nimmagadda

Frontiers in Oncology

doi 10.3389/fonc.2021.796962

7,867 views
11 citations

Brief Research Report

Published on 02 Feb 2022

Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse

in Hematologic Malignancies

Binod Dhakal
Shruti Sharma
Mustafa Balcioglu
Svetlana Shchegrova
Meenakshi Malhotra
Bernhard Zimmermann
Paul R. Billings
Alexandra Harrington
Himanshu Sethi
Alexey Aleshin

Frontiers in Oncology

doi 10.3389/fonc.2022.786451

7,700 views
21 citations

Mini Review

Published on 01 Feb 2022

Toward a Better Classification System for NK-LGL Disorders

in Hematologic Malignancies

Gaëlle Drillet
Cédric Pastoret
Aline Moignet
Thierry Lamy
Tony Marchand

Frontiers in Oncology

doi 10.3389/fonc.2022.821382

9,909 views
10 citations

Original Research

Published on 01 Feb 2022

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)

in Hematologic Malignancies

Anna Sicuranza
Ilaria Ferrigno
Elisabetta Abruzzese
Alessandra Iurlo
Sara Galimberti
Antonella Gozzini
Luigiana Luciano
Fabio Stagno
Antonella Russo Rossi
Nicola Sgherza

Frontiers in Oncology

doi 10.3389/fonc.2022.835563

4,107 views
16 citations

Review

Published on 01 Feb 2022

Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions

in Hematologic Malignancies

Long Su
Yuan-Yuan Shi
Zeng-Yan Liu
Su-Jun Gao

Frontiers in Oncology

doi 10.3389/fonc.2022.806137

35,171 views
45 citations

Brief Research Report

Published on 31 Jan 2022

Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation

in Hematologic Malignancies

Valentín Ortiz-Maldonado
Gerard Frigola
Marta Español-Rego
Olga Balagué
Nuria Martínez-Cibrián
Laura Magnano
Eva Giné
Mariona Pascal
Juan G. Correa
Alexandra Martínez-Roca

Frontiers in Oncology

doi 10.3389/fonc.2022.828471

8,268 views
29 citations

Original Research

Published on 27 Jan 2022

Targeting Thyrointegrin αvβ3 Using Fluorobenzyl Polyethylene Glycol Conjugated Tetraiodothyroacetic Acid (NP751) in Acute Myeloid Leukemia

in Hematologic Malignancies

Noureldien H. E. Darwish
Gennadi V. Glinsky
Thangirala Sudha
Shaker A. Mousa

Frontiers in Oncology

doi 10.3389/fonc.2021.793810

3,825 views
5 citations

Systematic Review

Published on 27 Jan 2022

Cardiac Infiltration as the First Manifestation of Acute Lymphoblastic Leukemia: A Systematic Review

in Hematologic Malignancies

Zhi Luo
Jun Cheng
Yanggan Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.805981

7,866 views
14 citations

Review

Published on 27 Jan 2022

Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead

in Hematologic Malignancies

Basak Aru
Mojdeh Soltani
Cemil Pehlivanoglu
Ege Gürlü
Mazdak Ganjalikhani-Hakemi
Gülderen Yanikkaya Demirel

Frontiers in Oncology

doi 10.3389/fonc.2022.789728

3,181 views
5 citations

2,059 articles

articles

Epidemiologic Characteristics, Prognostic Factors, and Treatment Outcomes in Primary Central Nervous System Lymphoma: A SEER-Based Study

Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis

T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?

PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma

Impact of Low-Burden TP53 Mutations in the Management of CLL

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment

The Roles of IRF-8 in Regulating IL-9-Mediated Immunologic Mechanisms in the Development of DLBCL: A State-of-the-Art Literature Review

What Clonal Hematopoiesis Can Teach Us About MDS

Mutant NPM1-Regulated FTO-Mediated m6A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis

Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report

Prognostic Value of Radiomic Features of 18F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells

A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children

Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists

Editorial: New Insights into the Complexity of Tumor Immunology in B-cell Malignancies: Tumor Immunology and Immunotherapy

Diffuse Large B-Cell Lymphoma: Clinical Presentation and Treatment Outcomes From the OncoCollect Lymphoma Registry

Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse

Toward a Better Classification System for NK-LGL Disorders

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)

Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions

Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation

Targeting Thyrointegrin αvβ3 Using Fluorobenzyl Polyethylene Glycol Conjugated Tetraiodothyroacetic Acid (NP751) in Acute Myeloid Leukemia

Cardiac Infiltration as the First Manifestation of Acute Lymphoblastic Leukemia: A Systematic Review

Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead